PML/RARa (AML - M3) (APL) Qualitative

Acute promyelocytic leukemia (APL) with PML‑RARA is a distinct subtype of acute myeloid leukemia caused by a t(15;17) translocation that creates a PML‑RARA fusion gene. The fusion blocks promyelocyte maturation and often leads to severe bleeding and coagulopathy. It responds remarkably to targeted therapy (all‑trans retinoic acid and arsenic trioxide), giving high remission rates when diagnosed and treated promptly.

The APML RARA test detects the PML‑RARA fusion gene from the t(15;17) translocation that causes acute promyelocytic leukemia (APML). It confirms diagnosis, directs targeted treatment with all‑trans retinoic acid and arsenic trioxide, and is used to monitor treatment response and minimal residual disease. Testing is done by molecular and cytogenetic methods (RT‑PCR, FISH, karyotype) on blood or bone marrow.

Type M3 leukemia, also called acute promyelocytic leukemia (APL), is a subtype of acute myeloid leukemia marked by accumulation of abnormal promyelocytes and a characteristic t(15;17) PML‑RARA genetic fusion. It often presents with bleeding, bruising, infection and anemia and carries high risk of coagulopathy/DIC. APL is treated with all‑trans retinoic acid and arsenic trioxide, offering a favorable prognosis when diagnosed promptly.

PML is the promyelocytic leukemia protein, a tumor suppressor that helps form nuclear bodies and regulate cell growth. RARA is the retinoic acid receptor alpha, a nuclear receptor controlling myeloid cell differentiation. A chromosomal translocation t(15;17) fuses PML and RARA into PML–RARA, blocking promyelocyte maturation and causing acute promyelocytic leukemia; it’s treatable with ATRA and arsenic.

Acute promyelocytic leukemia (APL) is a medical emergency: it can cause life‑threatening bleeding and clotting problems early on, but it is also one of the most curable leukemias with modern targeted therapy (ATRA and arsenic trioxide). Prompt diagnosis and urgent treatment greatly improve survival, though early complications and treatment side effects require intensive monitoring and specialist care.

High-risk acute promyelocytic leukemia (APL) is defined by a presenting white blood cell count >10,000/µL. It confers higher risk of life‑threatening bleeding, differentiation syndrome and early death. Management requires urgent, intensive therapy (ATRA plus arsenic trioxide, sometimes with chemotherapy) and vigilant supportive care including transfusions, coagulation management, infection prevention and close monitoring for differentiation syndrome.